These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 9460604)

  • 21. [Correction of cardiotoxic effect of chronic alcoholic intoxication by GABA-ergic compounds].
    Perfilova VN; Tiurenkov IN; Lebedeva SA
    Kardiologiia; 2007; 47(6):46-9. PubMed ID: 18260875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A neuroprotective effect of the herbal drug neurofit in alcoholic intoxication].
    Dashinamzhilov ZhB; Lonshakova KS; Ubasheev IO; Nikolaev SM; Gulevich AA
    Patol Fiziol Eksp Ter; 2007; (4):27-9. PubMed ID: 18154085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Preclinical prognosis of pyracetam and picamilon safety based on acute toxicity data].
    Bugaeva LI; Spasov AA; Verovskiĭ VE; Iezhitsa IN
    Eksp Klin Farmakol; 2003; 66(4):43-6. PubMed ID: 14558352
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Experimental and clinical rationale for complex treatment of mental disorders in clean-up workers of the Chernobyl nuclear plant accident].
    Neznamov GG; Koshelev VV; Voronina TA; Trofimov SS
    Eksp Klin Farmakol; 2002; 65(2):12-6. PubMed ID: 12109283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-field MRS study of GABA, glutamate and glutamine in social anxiety disorder: response to treatment with levetiracetam.
    Pollack MH; Jensen JE; Simon NM; Kaufman RE; Renshaw PF
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):739-43. PubMed ID: 18206286
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimyoclonic efficacy of piracetam in idiopathic generalized epilepsy.
    Khani YA; Andermann F; Andermann E
    Epilepsia; 2005 Jul; 46(7):1145-6. PubMed ID: 16026569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The pharmacokinetics of the dipeptide analog of piracetam with nootropic activity GVS-111 and of its basic metabolites].
    Boĭko SS; Zherdev VP; Dvorianinov AA; Gudasheva TA; Ostrovskaia RU; Voronina TA; Rozantsev GG; Seredenin SB
    Eksp Klin Farmakol; 1997; 60(2):53-5. PubMed ID: 9206571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ["Fast" and "slow" components of psychotropic activity of the drugs with nootropic effects].
    Neznamov GG; Siuniakov SA; Davydova IA; Teleshova ES
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(6):33-7. PubMed ID: 10900686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Nootropic agents: a review of their pharmacological properties, mechanisms of action and therapeutic uses].
    Caminero AB; Frank A; Barreiro P; Díez Tejedor E
    Rev Clin Esp; 1995 Mar; 195(3):172-9. PubMed ID: 7754152
    [No Abstract]   [Full Text] [Related]  

  • 30. Dose-effect relationship of idebenone in an experimental cerebral deficit model. Pilot study in healthy young volunteers with piracetam as reference drug.
    Schaffler K; Hadler D; Stark M
    Arzneimittelforschung; 1998 Jul; 48(7):720-6. PubMed ID: 9706371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levetiracetam for the treatment of alcohol withdrawal syndrome: an open-label pilot trial.
    Krebs M; Leopold K; Richter C; Kienast T; Hinzpeter A; Heinz A; Schaefer M
    J Clin Psychopharmacol; 2006 Jun; 26(3):347-9. PubMed ID: 16702910
    [No Abstract]   [Full Text] [Related]  

  • 32. [The consequences of closed traumatic brain injury and piracetam efficacy in their treatment in adolescents].
    Zavadenko NN; Guzilova LS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(3):43-8. PubMed ID: 18427539
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer's type.
    Kyomen HH; Whitfield TH; Baldessarini RJ
    J Clin Psychopharmacol; 2007 Aug; 27(4):408-10. PubMed ID: 17632234
    [No Abstract]   [Full Text] [Related]  

  • 34. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
    Tariska P; Paksy A
    Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Changes in the reaction to damage to the case in caddisfly larvae under the influence of piracetam].
    Inozemtsev AN; Nepomniashchikh VA
    Zh Vyssh Nerv Deiat Im I P Pavlova; 1995; 45(6):1211-3. PubMed ID: 8585313
    [No Abstract]   [Full Text] [Related]  

  • 36. Piracetam therapy for Down syndrome: a rush to judgment?
    Black SL
    Arch Pediatr Adolesc Med; 2001 Oct; 155(10):1176; author reply 1177-8. PubMed ID: 11576019
    [No Abstract]   [Full Text] [Related]  

  • 37. [Comparison of neurotropic and stress-protective properties of piracetam and the derivative pyrido]1,2-a]pyrimidine].
    Kozlovskaia MM; Inozemtsev AN; Nikitin SV; Gochmuradov AG; Iakushev RA; Chabak-Gorbach R
    Biull Eksp Biol Med; 1995 Mar; 119(3):299-301. PubMed ID: 7795202
    [No Abstract]   [Full Text] [Related]  

  • 38. Piracetam study: poorly designed and misinterpreted.
    Croom J
    Arch Pediatr Adolesc Med; 2001 Oct; 155(10):1176-8. PubMed ID: 11576020
    [No Abstract]   [Full Text] [Related]  

  • 39. Brain neurotransmitter receptor binding and nootropic studies on Indian Hypericum perforatum Linn.
    Kumar V; Khanna VK; Seth PK; Singh PN; Bhattacharya SK
    Phytother Res; 2002 May; 16(3):210-6. PubMed ID: 12164263
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Does treatment with piracetam in stroke patients with aphasia make sense?].
    Schmidtke K
    Dtsch Med Wochenschr; 2002 Dec; 127(49):2636. PubMed ID: 12469280
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.